Modified Arrestin-1 Enhances Photoreceptor Survival
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Arrestin-1 variants with reduced inhibitory effect on enolase-1 catalytic activity while maintaining binding affinity are needed to address the energy demands of photoreceptors in retinal degenerative diseases, as existing interactions between arrestin-1 and enolase-1 significantly reduce glycolytic efficiency, impacting photoreceptor function and survival.
Innovation Solution
Development of arrestin-1 variants with specific amino acid substitutions at positions 361 and 362, such as E361G/D362G, which reduce the inhibitory effect on enolase-1 catalytic activity by less than 25% while retaining binding capability, allowing for increased glycolytic activity and improved photoreceptor function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If arrestin-1 binds to enolase-1, then photoreceptor function is regulated, but enolase-1 catalytic activity is inhibited by 25%, reducing glycolytic efficiency
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues (Glu361 and Asp362) in arrestin-1 to alter its interaction with enolase-1. These chemical parameter changes at the molecular level reduce the inhibitory effect on enolase-1 catalytic activity while preserving the regulatory function, thereby resolving the contradiction between reliability and productivity.
Solution Approach 2:
The invention applies local quality by making targeted modifications only at specific binding interface residues (positions 361 and 362) of arrestin-1, rather than altering the entire protein. This localized modification approach maintains the overall regulatory function while specifically improving the catalytic activity of enolase-1 at the interaction site.
2Reliability
If arrestin-1 inhibits enolase-1 activity, then binding interaction is maintained, but ATP production decreases, impacting photoreceptor survival
Solution Approach 1:
The patent changes the chemical parameters of arrestin-1 by substituting Glu361 and Asp362 with amino acids that have different charge properties. This parameter change reduces the inhibitory interaction while maintaining binding, thereby improving ATP production without completely abolishing the binding interaction between arrestin-1 and enolase-1.
3Reliability
If wild-type arrestin-1 is expressed, then photoreceptor function is maintained, but glycolytic activity is reduced, limiting photoreceptor survival in degenerative diseases
Solution Approach 1:
The patent applies parameter changes by creating arrestin-1 variants with modified amino acid sequences at positions 361 and 362. These parameter changes improve glycolytic activity and ATP production, thereby enhancing photoreceptor survival while maintaining photoreceptor function, which is critical for treating retinal degenerative diseases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified arrestin-1 variants enhance glycolytic activity, increase ATP and NADH levels, and promote photoreceptor survival, offering potential therapeutic benefits for retinal degenerative diseases like retinitis pigmentosa and cone-rod dystrophies by preserving scotopic and photopic vision and delaying photoreceptor degeneration.
Implementation Method 1
arrestin-1 interacts with enolase-1... Binding of arrestin-1 to enolase-1 affects the catalytic activity of enolase
Implementation Method 2
Enolase-1, which catalyzes the interconversion of 2-phosphoglycerate to phosphoenolpyruvate, is one of the key enzymes in the glycolysis pathway
Implementation Method 3
photoreceptors metabolize 80-96% of available glucose into lactic acid via aerobic glycolysis
Implementation Method 4
arrestin-1 variants with specific amino acid substitutions at positions 361 and 362, such as E361G/D362G, which reduce the inhibitory effect on enolase-1 catalytic activity
Implementation Method 5
The modified arrestin-1 variants enhance glycolytic activity, increase ATP and NADH levels, and promote photoreceptor survival
Data Source
AI summary
Arrestin-1 variants having reduced inhibitory effects on enolase-1 catalytic activity are described. The arrestin-1 variants can be used in the treatment of retinal degenerative diseases.